NorthStar Medical Technologies Builds the Ac-225 Supply Chain

NorthStar Medical Technologies is building an integrated supply chain for radiopharmaceutical developers, combining commercial-scale radioisotope production with drug-development and cGMP manufacturing services on one campus in Beloit, Wisconsin. Founded in 2006 and led by President and CEO Frank Scholz, Ph.D., the company produces copper-67 and no-carrier-added actinium-225 while operating a radiopharmaceutical contract development and manufacturing organization.

NorthStar matters now because targeted radiopharmaceutical programs need more than an isotope vendor. Developers must coordinate radioactive material, analytical testing, regulatory documentation, drug-product manufacturing, packaging, and delivery while the isotope is actively decaying. NorthStar is betting that co-location can turn those handoffs into one operating system.

The company entered 2026 with commercial-scale actinium-225 production, an FDA-accepted Type II Drug Master File, expanded customer programs, and a new growth-capital facility of up to $185M from Hercules Capital. Those milestones do not remove the execution risk of scaling a regulated manufacturing platform. They do show how NorthStar is moving from a domestic isotope-supply project into a broader piece of precision-oncology infrastructure.

From Medical Isotope Shortages to Radiopharmaceutical Infrastructure

NorthStar Medical Technologies was founded in 2006 to address persistent supply problems in the U.S. nuclear-medicine market. Its early work focused on domestic, non-uranium production of molybdenum-99, the parent isotope used to generate technetium-99m for diagnostic imaging. That history matters because reliability has always been the product, even when the isotope changed.

Today, NorthStar's growth strategy is centered on therapeutic and theranostic radioisotopes, particularly no-carrier-added actinium-225 and copper-67. Actinium-225 emits alpha particles that can be attached to targeting molecules under development for precision cancer treatment. Copper-67 can support both imaging and therapy applications. NorthStar produces the isotopes using electron-accelerator technology rather than the uranium-fission pathways historically associated with some medical isotope supply.

This is a difficult business by design. The product is radioactive, time-sensitive, regulated, and technically demanding. A reliable supply chain must work across production, purification, quality release, manufacturing, shipping, and customer schedules. NorthStar's long operating history gives it a different starting point from a software-era startup entering the category because the market suddenly looks attractive.

What NorthStar Builds on Its Beloit Campus

NorthStar's strategic asset is a 55-acre campus that puts isotope production and radiopharmaceutical manufacturing in one place. The company's radioisotope manufacturing operation includes dual electron-beam accelerators, dedicated chemical processing, and analytical laboratory capabilities. Its actinium-225 facility covers roughly 30,000 square feet, while its CDMO facility spans about 52,000 square feet.

The radiopharmaceutical CDMO supports development from preclinical and early clinical work through later-stage and commercial manufacturing. Services include analytical development, process development, cGMP manufacturing suites, packaging, radioactive-material handling, and logistics. NorthStar says its campus is the only U.S. site combining commercial-scale, multi-radioisotope production and radiopharmaceutical development in one location.

Co-location is more than a real-estate story. Actinium-225 has a half-life of about 10 days. Every avoidable handoff consumes time and usable material. Keeping isotope production, drug-product manufacturing, quality systems, and outbound logistics close together can reduce coordination risk for pharmaceutical partners. In this market, elapsed time is part of product quality.

The Actinium-225 Scale-Up

NorthStar announced commercial-scale production of no-carrier-added actinium-225 in January 2026. Its process uses an electron accelerator to irradiate radium-226, creating radium-225 that is separated and allowed to decay into actinium-225. The company describes the resulting material as free of long-lived radioactive contaminants associated with some alternative production routes.

In April 2026, the U.S. Food and Drug Administration accepted NorthStar's Type II Drug Master File for its n.c.a. Ac-225. The file allows pharmaceutical partners to reference NorthStar's isotope information in their own regulatory submissions. The acceptance is not approval of a therapy, but it reduces one layer of documentation work for drug developers evaluating the material.

NorthStar reports supply and manufacturing agreements with more than 30 pharmaceutical and biotechnology companies. Publicly disclosed collaborations have included Convergent Therapeutics, Curadh MTR, Monopar Therapeutics, Alpha-9 Oncology, Clarity Pharmaceuticals, and BIOEMTECH. The company does not disclose the economics of most agreements or identify every customer, so the count is best treated as a company-reported measure of commercial engagement rather than audited revenue.

The up to $185M Hercules Capital facility, announced in September 2026 with $100M funded upfront, is designed to expand isotope production and clinical and commercial manufacturing. NorthStar also plans to bring a higher-capacity actinium-225 line online later in 2026. Capital is not merely a financing story here. It is part of production reliability in a market where facilities, accelerators, quality systems, and specialized teams must arrive before demand can be served.

Leadership Built for Regulated Scale

Frank Scholz, Ph.D. became President and CEO in June 2023 after serving as NorthStar's operating leader. His background spans pharmaceutical operations, quality, supply chain, alliance management, consulting, and integration work. That mix fits a company whose central challenge is coordinating complex systems rather than proving a single laboratory concept.

James T. Harvey, Ph.D., a NorthStar co-founder, serves as Senior Vice President and Chief Science Officer. Jeff Schaaf is Senior Vice President and Chief Technology Officer. Victor Miller, CFA, became Chief Financial Officer in December 2025, bringing life-sciences finance and investment-banking experience. Gauri Gupta, MBA, leads strategy and transformation, while Kathy Spencer-Pike serves as Chief Commercial Officer.

The leadership structure reflects the company's next phase. Scientific credibility remains essential, but NorthStar also needs capital discipline, commercial execution, quality systems, and customer-program management. Scaling radiopharmaceutical infrastructure is not a founder mythology exercise. It is controlled execution across dozens of interdependent functions.

Hiring Signals Where NorthStar Is Expanding

NorthStar's current careers page features roles including Senior Director, Commercial for the CDMO business and Director, Quality. The company describes itself as headquartered in Beloit with additional facilities in Madison, Wisconsin. Its public employee proposition emphasizes entrepreneurial problem-solving, collaboration, and a mission tied to patient access.

The open roles are more useful as operating signals than as recruiting copy. Commercial CDMO leadership points to a push for more partner programs. Quality leadership points to the burden of running regulated isotope and drug-product manufacturing at greater scale. In a radiopharmaceutical business, sales capacity without quality capacity is a promise waiting to break.

NorthStar's workforce also sits in a specialized labor market. The company needs nuclear scientists, engineers, quality professionals, manufacturing operators, regulatory specialists, logistics experts, and commercial leaders who can work across technical and customer boundaries. Building that team in parallel with physical capacity may determine whether the campus model becomes a durable advantage.

Why NorthStar Matters to the Radiopharmaceutical Market

The radiopharmaceutical sector has attracted capital because targeted medicines can pair biological precision with radioactive payloads. Yet the category's growth still depends on industrial questions that do not fit neatly into a biotech pitch deck: Where will the isotope come from? Can it be produced consistently? Can a manufacturer turn it into a patient-ready dose on schedule? Can the quality package survive regulatory review?

NorthStar is building around those questions. Its advantage is not one isotope or one building. It is the attempt to connect domestic production, regulatory documentation, development services, commercial manufacturing, and logistics before the broader market reaches full scale.

The risk is equally clear. NorthStar must bring new capacity online, maintain quality, support many customer programs, and manage a capital-intensive footprint while therapies advance on uncertain clinical timelines. The company-reported customer count and capacity plans are meaningful signals, not guarantees.

That tension is what makes NorthStar worth watching. The company spent two decades learning that medical isotopes are an infrastructure problem disguised as a chemistry problem. If its integrated campus can make actinium-225 supply and radiopharmaceutical manufacturing more predictable, NorthStar will be selling something more valuable than material. It will be selling time.